<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Best evidence statement (BESt). Screening of hypertension in pediatric patients with diabetes.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Screening of hypertension in pediatric patients with diabetes. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2011 Apr 5. 12 p.  [7 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes with other coma, type I [juvenile type], not stated as uncontrolled  (250.31); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30); Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled  (250.71); Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled  (250.70); Screening for hypertension  (V81.1)"/><FieldValue Value="MSH: Antihypertensive Agents ; Blood Cell Count ; Blood Chemical Analysis ; Blood Pressure Determination ; Diabetes Complications ; Diabetes Mellitus ; Diabetes Mellitus, Type 1 ; Diabetes Mellitus, Type 2 ; Diabetic Angiopathies ; Diet Therapy ; Exercise ; Hypertension ; Urinalysis "/><FieldValue Value="MTH: Antihypertensive Agents ; blood cell count ; Blood Chemical Analysis ; Blood pressure determination ; Complications of Diabetes Mellitus ; Diabetes Mellitus ; Diabetes Mellitus, Insulin-Dependent ; Diabetes Mellitus, Non-Insulin-Dependent ; Diet therapy ; Encounter due to screening for hypertension ; Exercise ; Hypertensive disease ; urinalysis "/><FieldValue Value="SNOMEDCT_US: Blood cell count  (88308000); Blood chemistry  (166312007); Blood pressure taking  (46973005); Diabetes mellitus  (73211009); Diabetic complication  (74627003); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Hypertensive disorder  (38341003); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Type 1 diabetes mellitus  (46635009); Type 2 diabetes mellitus  (44054006); Urinalysis  (167217005); Urinalysis  (27171005)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pediatrics" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate in pediatric patients (ages 3 to 18 years) with diabetes what is the optimal screening of hypertension in children and adolescents to reduce the risk of cardiovascular complications&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Pediatric patients (ages 3 to 18 years) with diabetes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Management/Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screening for hypertension at each clinic visit &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determine blood pressure percentile &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary interventions and exercise &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory parameters, including basic metabolic panel, complete blood count, and urinalysis &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Risk of cardiovascular complications&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Initial search&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;DATABASE: Ovid: Medline &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;OVID FILTERS&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Publication dates: 1996 to May 21, 2010 &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Limits: English language, all child (0 to 18 years) &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;SEARCH TERMS &amp;amp; MeSH TERMS exp *Diabetes Mellitus/ AND exp blood pressure/ AND exp children / search results filtered for: diagnosis subheading OR treatment outcome.mp. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Search for synthesized evidence&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;DATABASE: Ovid: Medline &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;OVID FILTERS&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Publication dates: 1996 to Mar 3, 2010 &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Limits: English language, All child (0 to 18 years) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Publication type: (guideline or meta-analysis or practice guidelines or systematic review).pt. or &quot;the cochrane library&quot;.jn. or &quot;cochrane database of systematic reviews&quot;.jn. &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;SEARCH TERMS &amp;amp; MeSH TERMS exp Diabetes Mellitus/ or Diabetes Mellitus, Experimental/ or Diabetes, Gestational/ or Diabetes Insipidus, Neurogenic/ or Diabetes Complications/ or Diabetes Insipidus, Nephrogenic/ or Diabetes Mellitus, Lipoatrophic/ or &quot;National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)&quot;/ or Diabetes Insipidus/ &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5 or 5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Three main guidelines were identified: 1) the American Heart Association (AHA) Scientific Statement entitled Cardiovascular Risk Reduction in High-Risk Pediatric Patients, 2) Treatment guidelines from the American Diabetes Association (ADA) regarding children and adolescents, and 3) Diagnosis, Evaluation and Treatment guidelines from the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (The Fourth Report). These guidelines were appraised using the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument, and the results by domain were:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: AGREE Appraisal - Results by Domain&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;AGREE Domains&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;ADA&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;AHA&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Fourth Report&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Scope and Purpose&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;100%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;52%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;64%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Stakeholder Involvement&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;53%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;67%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;33%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Rigor of Development&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;59%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;81%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;39%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Clarity and Presentation&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;81%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;86%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;77%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Applicability&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;15%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;56%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;17%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Editorial Independence&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;100%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;72%&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;17%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;These three guidelines have clear pediatric-focused recommendations that are not directly based on evidence-based outcome data but were generated by consensus expert opinion or extrapolation from adult evidence. The recommendations developed for this best evidence statement (BESt) are primarily based on a combination of local consensus and recommendations from the AHA guidelines, ADA guidelines, and The Fourth Report.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or visa-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence (see note above) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to patient (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Reviewed against quality criteria by two independent reviewers&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of evidence (1a-5b) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients with diabetes &amp;ge;3 years of age be screened for hypertension at each clinic visit (Local Consensus, 2010 [5]; American Diabetes Association [ADA], 2010 [5a]; Kavey et al., 2006 [5a]; National High Blood Pressure Education Program Working Group [NHBPEPWG], 2004 [5b]) and receive appropriate follow-up if the blood pressure is &amp;ge;90th percentile by sex, age and height (see management algorithms in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended to determine blood pressure percentile by sex, age and height percentile (NHBPEPWG, 2004 [5b]). (See Appendix 1 in the original guideline document.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that if blood pressure (systolic or diastolic) is:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&amp;lt;90th percentile by sex, age and height (normal), no intervention is needed &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&amp;ge;90-95th percentile by sex, age and height percentile (prehypertensive range) (See Algorithm 1 in the original guideline document for diagnosis and management.) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Between the 95th-99th percentile by sex, age and height percentile (stage 1 hypertension range) (See Algorithm 2 in the original guideline document for the diagnosis and management.) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&amp;ge; the 99th percentile + 5mmHg by sex, age and height (stage 2 hypertension range) (See Algorithm 3 in the original guideline document for the diagnosis and management.)&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: For any of the above hypertension diagnoses, you must have abnormal blood pressure readings on three separate occasions. (See algorithms in the original guideline document for details.)&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;(Local Consensus, 2010 [5]; ADA, 2010 [5a]; Kavey et al., 2006 [5a]; NHBPEPWG 2004 [5b])&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that treatment of blood pressure (systolic or diastolic blood pressure) &amp;ge; the 90th percentile for age, sex, and height include dietary intervention (see Appendix 2 in the original guideline document) and exercise aimed at weight control and increased physical activity, as appropriate (Local Consensus, 2010 [5]; ADA, 2010 [5a]; Kavey et al., 2006 [5a]; NHBPEPWG, 2004 [5b]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that if target blood pressure (&amp;lt;130/80 or &amp;lt; the 90th percentile for age, sex, and height, whichever is lower) is not reached within 6 months of dietary intervention, pharmacologic treatment be initiated (Local Consensus, 2010 [5]; ADA, 2010 [5a]; Kavey et al., 2006 [5a]; NHBPEPWG, 2004 [5b]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that if blood pressure (systolic or diastolic) is &amp;ge; the 95th percentile for age, sex and height or &amp;ge;130/80 mmHg, pharmacologic therapy be initiated as soon as the diagnosis is confirmed (Local Consensus, 2010 [5]; ADA, 2010 [5a]; Kavey et al., 2006 [5a]; NHBPEPWG, 2004 [5b]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that if a diagnosis of prehypertension (&amp;ge;90th percentile) or hypertension (&amp;ge;95th percentile) is confirmed, the following screening labs be drawn to rule out secondary hypertension: basic metabolic panel, complete blood count and urinalysis (NHBPEPWG, 2004 [5b]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5 or 5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or visa-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence (see note above) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to patient (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms are provided in the appendices of the original guideline document for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pre Hypertension Algorithm 1: (BP &amp;ge;90-95th %ile) - T1DM or type T2DM &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stage 1 Hypertension Algorithm 2: (BP &amp;ge;95-99th %ile) - T1DM and T2DM &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stage 2 Hypertension (greater than &amp;ge;99th %ile + 5mmHg) Algorithm 3 - T1DM and T2DM &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010 Jan;33 Suppl 1:S11-61. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20042772&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J, American Heart Association Expert Panel on Population and Prevention Science, American Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Nutrition, Physical Activity and Metabolism, American Heart Association Council on High Blood Pressure Research, American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on the Kidney in Heart Disease, Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology [trunc]. Circulation. 2006 Dec 12;114(24):2710-38. [401 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17130340&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National High Blood Pressure Education Program Working Group on High Blood Pressure in Children. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 Aug;114(2 Suppl):555-76. [138 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15286277&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American Heart Association and the American Diabetes Association emphasize the importance of early recognition of hypertension in children with diabetes. Cardiovascular disease is the major cause of morbidity and mortality for individuals with diabetes and the largest contributor to the direct and indirect costs of diabetes. Hypertension is a common comorbidity that coexists with diabetes and is a clear risk factor for the development of cardiovascular disease. Hypertension is common in youth with diabetes with prevalence reports documenting nearly 30% of youth between the age of 10-19 years having elevated blood pressure. Early education regarding cardiovascular health and early intervention in children with hypertension is critical to improving long term outcomes.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive practice guideline. These recommendations result from review of literature and practices current at the time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current revision of this document. This document is not intended to impose standards of care preventing selective variances from the recommendations to meet the specific and unique requirements of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Patient Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Screening of hypertension in pediatric patients with diabetes. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2011 Apr 5. 12 p.  [7 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Apr 5" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Cincinnati Children's Hospital Medical Center - Hospital/Medical Center" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cincinnati Children's Hospital Medical Center&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Group/Team Leader&lt;/em&gt;: Amy Sanghavi Shah, MD, Endocrinology&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Other Group/Team Members&lt;/em&gt;: Nancy Crimmins, MD, Endocrinology; Jessica Gahl, RD, Endocrinology; Karishma Tilton, RN, Endocrinology&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;James M. Anderson Center for Health Systems Excellence Support Personnel&lt;/em&gt;: Eloise Clark, MPH, MBA, Guidelines Program Administrator, Evidence Facilitator; Karen Vonderhaar, MS, RN, Guidelines Program Administrator, Methodologist&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88006&amp;amp;libID=87694&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Judging the strength of a recommendation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Jan. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/d7344329-03d0-45f3-b6ca-02c746a472ec.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Grading a body of evidence to answer a clinical question. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/bd6f4eea-825c-49c3-a0e5-3e66c54dc066.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table of evidence levels. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Feb 29. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/5ce396bf-fdcb-4c65-a9f2-1b9888d4fc7e.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Appendix 1 of the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88006&amp;amp;libID=87694&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt; contains blood pressure charts for boys and girls by age and height percentile.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition, a proposed outcome measure is available in the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88006&amp;amp;libID=87694&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hypertension (high blood pressure). Your child's health. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2009 Jul. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/health/info/heart/diagnose/hypertension.htm&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, information for patients on dietary treatment for blood pressure and a healthy heart is available in Appendix 2 of the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88006&amp;amp;libID=87694&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on September 21, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original full-text guideline, which is subject to the following copyright restrictions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Copies of this &lt;a href=&quot;http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/best.htm&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center (CCHMC)&lt;/a&gt; Best Evidence Statement (BESt) are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Examples of approved uses of the BESt include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to anyone involved in the organization's process for developing and implementing evidence based care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlinks to the CCHMC website may be placed on the organization's website &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or electronic documents; and &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to patients and the clinicians who manage their care &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Notification of CCHMC at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt; for any BESt adopted, adapted, implemented or hyperlinked by the organization is appreciated.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
